104 related articles for article (PubMed ID: 26648164)
1. CK0403, a 9‑aminoacridine, is a potent anti‑cancer agent in human breast cancer cells.
Sun YW; Chen KY; Kwon CH; Chen KM
Mol Med Rep; 2016 Jan; 13(1):933-8. PubMed ID: 26648164
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of the growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino)ethan-1-ol (CK0402) by Herceptin in SKBR-3 human breast cancer cells.
Sun YW; Niu TK; Yang JM; Kwon CH; Chen KY; Chen KM
Exp Ther Med; 2010 May; 1(3):513-518. PubMed ID: 22993569
[TBL] [Abstract][Full Text] [Related]
3. Caspase-dependent cell death mediates potent cytotoxicity of sulfide derivatives of 9-anilinoacridine.
Park SK; Kang H; Kwon CH
Anticancer Drugs; 2008 Apr; 19(4):381-9. PubMed ID: 18454048
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
De Iuliis F; Salerno G; Giuffrida A; Milana B; Taglieri L; Rubinacci G; Giantulli S; Terella F; Silvestri I; Scarpa S
Tumour Biol; 2016 Feb; 37(2):2603-11. PubMed ID: 26392111
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
7. Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.
Jandial DD; Krill LS; Chen L; Wu C; Ke Y; Xie J; Hoang BH; Zi X
Molecules; 2017 Mar; 22(3):. PubMed ID: 28335434
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the antimetastatic and anticancer activities of morin in HER2‑overexpressing breast cancer SK‑BR‑3 cells.
Lee KS; Lee MG; Nam KS
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 33982761
[TBL] [Abstract][Full Text] [Related]
9. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
[TBL] [Abstract][Full Text] [Related]
10. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
[TBL] [Abstract][Full Text] [Related]
11. Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway.
Bowers LW; Wiese M; Brenner AJ; Rossi EL; Tekmal RR; Hursting SD; deGraffenried LA
PLoS One; 2015; 10(12):e0145452. PubMed ID: 26709918
[TBL] [Abstract][Full Text] [Related]
12. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
13. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
14. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Seoane S; Montero JC; Ocaña A; Pandiella A
J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
16. RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER‑negative breast cancer models.
Yadav B; Taurin S; Larsen L; Rosengren RJ
Int J Oncol; 2012 Nov; 41(5):1723-32. PubMed ID: 22971638
[TBL] [Abstract][Full Text] [Related]
17. Α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling.
Zhuo RJ; Wang F; Zhang XH; Zhang JJ; Xu J; Dong W; Zou ZQ
Mol Med Rep; 2014 Mar; 9(3):993-8. PubMed ID: 24425042
[TBL] [Abstract][Full Text] [Related]
18. Anatolian honey is not only sweet but can also protect from breast cancer: Elixir for women from artemis to present.
Seyhan MF; Yılmaz E; Timirci-Kahraman Ö; Saygılı N; Kısakesen Hİ; Eronat AP; Ceviz AB; Bilgiç Gazioğlu S; Yılmaz-Aydoğan H; Öztürk O
IUBMB Life; 2017 Sep; 69(9):677-688. PubMed ID: 28695656
[TBL] [Abstract][Full Text] [Related]
19. Apigenin induces caspase-dependent apoptosis by inhibiting signal transducer and activator of transcription 3 signaling in HER2-overexpressing SKBR3 breast cancer cells.
Seo HS; Ku JM; Choi HS; Woo JK; Jang BH; Go H; Shin YC; Ko SG
Mol Med Rep; 2015 Aug; 12(2):2977-84. PubMed ID: 25936427
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells.
Rahman KW; Li Y; Wang Z; Sarkar SH; Sarkar FH
Cancer Res; 2006 May; 66(9):4952-60. PubMed ID: 16651453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
